There has been much discussion in recent days on medicines pricing in the UK. The UK has some of the most robust processes in the world for ensuring value for money on medicines.
Today, 4 June, sees the unveiling of the UK’s newest life sciences asset, Health Innovation Research Alliance Northern Ireland (HIRANI) at a BIO reception in Philadelphia.
In light of the Government's announcement of an extension to article 50, ABPI commented on the position regarding stockpiling of medicines in preparation for a 'no-deal'.
Haseeb Ahmad, Managing Director, UK, Ireland & Nordics Novartis Pharmaceuticals and Country President Novartis UK has been confirmed as the new President of the ABPI.
The Government will today announce at the ABPI Conference that the most promising treatments will be fast-tracked by the new and boosted Accelerated Access Collaborative. Medicines, technologies and diagnostic tools targeting key health problems will be prioritised. The ABPI welcomes the move.
The Migration Advisory Committee has published their full review of the shortage occupation list (SOL) and recommended that a number of fields be added to the list.
Life sciences is among a select group of highly innovative industries linked to science and tech which could be responsible for a new wave of growth worth an extra £14 billion a year to the UK economy by 2025.
Health Secretary Matt Hancock has announced that all opioid medicines in the UK will carry prominent warnings on the labels saying they can cause addiction.
The Department of Health and Social Care today published the 2019 update of their Implementation Plan for England for the UK Strategy for Rare Diseases. This sets out progress made against the original commitments in the Strategy.
A Europe-wide initiative to protect patients and public health from falsified or fake medicines goes live on Saturday 9 February 2019, making the medicines supply chain across Europe safer than ever before.